SETBP1 and atypical chronic myeloid leukemia, BCR-ABL1 negative: It is important to mention that the rate of response was low in aCML cases compared to MDS/MPN-U, but it is not clear if this is due to a less significant number of aCML cases (four out of a total of 35) or because of other mutations present in aCML cases that might affect the response to ruxolitinib, e.g., SETBP1.